公开(公告)号：US20100216863A1

公开(公告)日：2010-08-26

申请号：US11913807

申请日：2006-03-30

申请人： Anna Helgadottir ,  Hákon Hákonarson ,  Jeffrey R. Gulcher ,  Mark E. Gurney

发明人： Anna Helgadottir ,  Hákon Hákonarson ,  Jeffrey R. Gulcher ,  Mark E. Gurney

IPC分类号： A61K31/7088 ,  C12Q1/68 ,  A61K31/7105 ,  A61P9/10

CPC分类号： A61K31/225 ,  A61K31/366 ,  A61K31/401 ,  C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/172 ,  G01N2800/324

摘要： Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides methods of prophylaxis therapy for MI in human subjects having a race including black African ancestry by administering to the subject a composition comprising a therapeutically effective amount of MI therapeutic agent that inhibits leukotriene synthesis in vivo. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a statin and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.

摘要翻译： FLAP和LTA4H基因的多态性通过遗传关联分析显示为心肌梗死（MI）和ACS以及中风和PAOD的敏感性标志物。 描述了针对治疗和诊断应用的途径，用于鉴定那些处于发展中心，ACS，中风或PAOD风险的患者。 本发明还提供了通过向受试者施用包含治疗有效量的体内抑制白细胞三烯合成的MI治疗剂的组合物的组合，在具有包括黑非洲血统的种族的人类受试者中预防MI治疗的方法。 本发明还提供了包含白三烯合成抑制剂和他汀类的组合物以及使用这些组合物降低患有MI，ACS，中风和/或PAOD风险的人类受试者中的C-反应蛋白的方法。

公开(公告)号：US07851486B2

公开(公告)日：2010-12-14

申请号：US10830477

申请日：2004-04-22

申请人： Anna Helgadottir ,  Mark Gurney ,  Jeffrey R. Gulcher ,  Hákon Hákonarson

发明人： Anna Helgadottir ,  Mark Gurney ,  Jeffrey R. Gulcher ,  Hákon Hákonarson

IPC分类号： A61K31/47

CPC分类号： C12Q1/6883 ,  A61K38/00 ,  C07K14/4705 ,  C12Q2600/156 ,  G01N2800/324

摘要： Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described.

摘要翻译： 公开了心肌梗塞（MI）和染色体13q12上的位点的连锁。 特别地，通过遗传关联分析将该基因内的FLAP基因显示为MI和ACS以及中风和PAOD的易感基因。 描述了针对治疗和诊断应用的途径，用于鉴定那些处于发展中心，ACS，中风或PAOD风险的患者。

公开(公告)号：US08158362B2

公开(公告)日：2012-04-17

申请号：US11270804

申请日：2005-11-09

申请人： Anna Helgadottir ,  Hákon Hákonarson ,  Jeffrey R. Gulcher ,  Mark E. Gurney

发明人： Anna Helgadottir ,  Hákon Hákonarson ,  Jeffrey R. Gulcher ,  Mark E. Gurney

IPC分类号： C12Q1/68 ,  C07H21/04

CPC分类号： C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/172

摘要： Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides methods of prophylaxis therapy for MI in human subjects having a race including black African ancestry by administering to the subject a composition comprising a therapeutically effective amount of MI therapeutic agent that inhibits leukotriene synthesis in vivo. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a statin and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.

摘要翻译： FLAP和LTA4H基因的多态性通过遗传关联分析显示为心肌梗死（MI）和ACS以及中风和PAOD的敏感性标志物。 描述了针对治疗和诊断应用的途径，用于鉴定那些处于发展中心，ACS，中风或PAOD风险的患者。 本发明还提供了通过向受试者施用包含治疗有效量的体内抑制白细胞三烯合成的MI治疗剂的组合物的组合，在具有包括黑非洲血统的种族的人类受试者中预防MI治疗的方法。 本发明还提供包含白三烯合成抑制剂和他汀类的组合物以及使用这些组合物降低患有MI，ACS，中风和/或PAOD风险的人类受试者中的C-反应蛋白的方法。